Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jin Medical International (ZJYL) Raw Materials (2022 - 2025)

Jin Medical International (ZJYL) has disclosed Raw Materials for 4 consecutive years, with $2.1 million as the latest value for Q3 2025.

  • Quarterly Raw Materials rose 1.76% to $2.1 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $2.1 million through Sep 2025, up 1.76% year-over-year, with the annual reading at $2.1 million for FY2025, 1.76% up from the prior year.
  • Raw Materials hit $2.1 million in Q3 2025 for Jin Medical International, up from $2.1 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $3.3 million in Q3 2022 to a low of $2.1 million in Q3 2024.
  • Historically, Raw Materials has averaged $2.5 million across 4 years, with a median of $2.4 million in 2023.
  • Biggest five-year swings in Raw Materials: decreased 21.31% in 2024 and later grew 1.76% in 2025.
  • Year by year, Raw Materials stood at $3.3 million in 2022, then dropped by 20.04% to $2.6 million in 2023, then fell by 21.31% to $2.1 million in 2024, then rose by 1.76% to $2.1 million in 2025.
  • Business Quant data shows Raw Materials for ZJYL at $2.1 million in Q3 2025, $2.1 million in Q3 2024, and $2.6 million in Q3 2023.